Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lepu Biopharma / 乐普生物

Request full access

HK-listed oncology biologics — ADCs, IO and oncolytic virus platforms

ChinaFounded 2018Biotech & Life Sciences

About Lepu Biopharma / 乐普生物

Shanghai HK-listed oncology biologics OEM (Lepu Biopharma / 乐普生物; HKEX 2157) develops ADC platforms plus oncolytic-virus and immuno-oncology adjacency with end-to-end discovery-to-GMP manufacturing for China and partnered ex-China channels. Founded in 2018 and operating from Shanghai with Beijing manufacturing adjacency, the company commercializes oncology assets such as pucotenlimab while advancing ADC and IO clinical programs. Mid-size China ADC leftover beyond Mabwell FIX this pack and Pack 42 RemeGen FIX / Duality softer profiles.

Source: Dealroom company data

At a glance

Status
Operational
Employees
33
Open positions
None listed
Dealroom signal
42.8/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPOOther financing Feb 2022 $116M $116M Undisclosed ↗
SERIES BOther financing Aug 2020 $1.3B $5.2B Ping An Group · Chinese Reform Holdings Corporation · SDIC Unity Capital · Ping An Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Lepu Biopharma / 乐普生物 website traffic

Latest recorded traffic for Lepu Biopharma / 乐普生物 is 390 monthly website visits, up 69.6% over the last three months. Lepu Biopharma / 乐普生物's team grew 6.5% over the past year.

Latest monthly visits390 3-month web change+69.6% 1-year team growth+6.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Lepu Biopharma / 乐普生物 in its local ecosystem

Live from Dealroom

The Lepu Biopharma / 乐普生物 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Ping An Capital
  • Ping An Group
  • Chinese Reform Holdings Corporation
  • SDIC Unity Capital
  • Haitong Innovation Capital Management
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China81.3%
🇺🇸 United States12.5%
🇨🇦 Canada6.3%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lepu Biopharma / 乐普生物 on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lepu Biopharma / 乐普生物’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.